Illumina’s Alliance for Genomic Discovery added Alnylam Pharmaceuticals and continues to attract pharma partners seeking large, phenotyped genomic datasets for drug target discovery. The AGD has sequenced more than 250,000 genomes from Vanderbilt’s BioVU biobank with linked electronic health records and plans another 30,000 samples. Industry partners report using the data for target validation, phenotype queries and integrated proteomic plans, reinforcing commercial demand for population‑scale, clinically annotated genome resources.